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Abstract: Topical hypotensive therapy with both timolol and carbonic anhydrase inhibitors 
has been shown to be efficacious at reducing intraocular pressure. Many prospective studies 
have also suggested that carbonic anhydrase inhibitors augment ocular blood flow and vascular 
regulation independent of their hypotensive effects. Although consistent in their findings, these 
studies must be cautiously interpreted due to the limitations of study design and specific blood 
flow imaging modalities. The purpose of this review is to appraise and critically evaluate the 
current body of literature investigating the effects of combined treatment with topical carbonic 
anhydrase inhibitors and timolol in patients with glaucoma with respect to ocular blood flow, 
visual function, and optic nerve head structure.
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Introduction
Open angle glaucoma and vascular risk factors
Glaucoma is a chronic progressive optic neuropathy resulting in optic nerve dam-
age and irreversible loss of visual function for which elevated intraocular pressure 
(IOP) is currently the only modifiable risk factor.1 Several large studies including the 
Ocular Hypertension Study,2 the Early Manifest Glaucoma Trial,3,4 the Collaborative 
  Normal Tension Glaucoma Study,5 the Advanced Glaucoma Intervention Study,6,7 and 
the Collaborative Initial Glaucoma Treatment Study8 have emphasized that despite 
the benefits of IOP reduction, many patients with open angle glaucoma (OAG) will 
  continue to experience disease progression. The existence of normal tension glau-
coma (NTG) further suggests that other risk factors may play an important role in the 
  disease process. Other important risk factors have been recently established, and there 
is increasing evidence that ocular blood flow changes and other vascular risk factors 
play a large role in the development and progression of glaucoma.
Vascular abnormalities have long been suggested as a possible contributing factor 
to the pathophysiology of OAG. Several prospective clinical trials have revealed blood 
flow alterations in various tissue beds of the eye in glaucoma patients. Chung et al 
found that NTG is characterized by a substantial decrease in capillary perfusion of 
the peripapillary retina.9 Yin et al demonstrated significantly delayed choroidal filling 
time in primary OAG patients.10 Similarly, several studies have revealed blood flow 
alterations in the retrobulbar circulations of glaucoma patients.11–14
One of the most recognized vascular risk factors in glaucoma is ocular perfusion 
pressure (OPP). OPP is calculated as the difference between two-thirds of the mean Clinical Ophthalmology 2010:4 234
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on beta blockers and ocular hemodynamics are thoroughly 
discussed in several previously published articles.25–27
Carbonic anhydrase inhibitors
Carbonic anhydrase inhibitors (CAI) are another class of 
topical medications commonly prescribed for the treatment 
of OAG. Carbonic anhydrase, an enzyme integral to fluid 
balance in the human body, catalyzes the reversible reac-
tion of carbon dioxide (CO2) and water (H2O) into carbonic 
acid. Carbonic acid then further dissociates into protons and 
bicarbonate. In the ciliary body of the eye, bicarbonate ions 
formed during this reaction are actively transported across the 
ciliary epithelial membrane, drawing water into the posterior 
chamber via osmosis, forming aqueous humor. CAI bind to 
the active site of the enzyme and prevent catalytic conversion 
of CO2 and H2O into bicarbonate and a proton, and vice versa. 
This process disrupts normal physiologic mechanisms and 
leads to different effects in different tissues. In the eye, CAI 
specifically inhibit the CA-II isoform, which is concentrated 
in the ciliary body. Inhibition of this enzyme has been shown 
to decrease IOP by decreasing aqueous humor production.
The effects of CAI on vascular tissue are also of great 
interest. Originally, systemic CAI were utilized for the 
treatment of patients with OAG. Early research on one 
such systemic CAI, acetazolamide (AZA), documented 
its vasodilatory effects on the cerebrovascular circulation. 
Laux et al demonstrated that intravenous administration 
of AZA significantly increases cerebral blood flow (CBF) 
through increasing PaCO2 and decreasing cerebral oxygen 
consumption by restricting the Bohr Effect in capillaries of 
the brain. Well established in the literature, seven indepen-
dent studies have reported a significant increase in CBF after 
intravenous administration of AZA.35 These data led others 
to propose that a similar mechanism might be present in 
the retinal circulation as the two vascular tissue beds share 
many similarities. Stanescu et al demonstrated that b-wave 
amplitude, a measure of bipolar cell function in the retina, 
as measured by electroretinogram significantly increased 
following intravenous administration of AZA.36 The known 
vasoactive properties of CAI have inspired extensive study 
of the effects of topical CAI on ocular blood flow, with 
dorzolamide and brinzolamide being the most prescribed 
and researched.37
Combined treatments
The Ocular Hypertensive Treatment Study2 and the 
  Collaborative Initial Glaucoma Treatment Study38 showed 
that 40% and 75% of patients, respectively, required two or 
arterial blood pressure (BP) and IOP and is the driving force 
of ocular blood flow. OPP is often subdivided into systolic 
perfusion pressure (SPP) and diastolic perfusion pressure 
(DPP). Lower OPP has recently been determined to be an 
independent risk factor for OAG, a consensus point reached 
by the 2009 World Glaucoma Association.15 This was due, 
in part to significant findings from large studies such as the 
Baltimore Eye Survey, where subjects with DPP less than 
30 mmHg were 6 times more likely to develop primary OAG 
than subjects with a DPP of greater than 50 mmHg.16 This 
finding is consistent with the Barbados Eye Study17 and the 
Egna-Neumarkt Study.18 Additionally, evidence suggests that 
subjects with glaucoma fail to adapt to changes in either IOP 
or BP that cause fluctuations in OPP, ultimately resulting in 
unstable blood flow to the retina and optic nerve head.19
Topical OAG therapies
β-Blockers
Topical OAG therapies have long been utilized with a pri-
mary goal of lowering IOP. In order to be efficacious, such 
therapies must penetrate the anterior surface of the eye, reach 
critical concentrations in the tissue of interest, and exert the 
desired physiologic effect. Topical medications may also 
be absorbed systemically leading to additional desired or 
adverse effects on ocular tissue and vasculature.
One of the most commonly prescribed topical OAG 
therapies is timolol maleate, a non-selective β-adrenergic 
receptor blocking agent. Timolol works to reduce IOP by 
blocking β-adrenergic receptors on the ciliary epithelium 
thereby reducing aqueous humor production. In addition 
to production of aqueous humor, β-adrenergic receptors 
are involved in the mediation of vascular smooth muscle 
relaxation.20 Blockade of β-adrenergic receptors have been 
previously shown to induce vasoconstriction in various tis-
sues.20–22 Within the eye, β-adrenergic receptors have been 
identified in the retina and optic nerve head tissues.23,24 This 
has led to a concern that β-adrenergic receptor blocking 
agents may cause local vasoconstriction in addition to IOP 
reduction.24 The effect of timolol on ocular blood flow in 
glaucoma patients however has been controversial. Several 
studies utilizing diverse measurement techniques have 
found varying results, ranging from significantly decreased 
to significantly increased effects on ocular blood flow, with 
many showing no significant change.25–34 There has not been 
a consistent effect of timolol in altering ocular blood flow, 
therefore timolol is often considered limited in terms of its 
affects on the ocular vasculature. Further detailed information Clinical Ophthalmology 2010:4 235
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more medications to adequately control their IOP. This illus-
trates that although β-blocker therapy is frequently used as an 
initial therapy, it may be inadequate to achieve optimal IOP 
reduction. Several large studies have shown that a combined 
treatment with dorzolamide and timolol reduces aqueous 
production and IOP to a greater degree than is achieved by 
either agent alone.39,40 Similarly, in a large randomized con-
trolled trial including 523 subjects, a fixed combination of 
brinzolamide and timolol was shown to be superior to either 
drug used alone with regards to its IOP-lowering efficacy.41
It is important to acknowledge that there are many classes 
of ocular hypotensive agents used for the management of 
OAG. Many drugs increase perfusion pressure by reducing 
IOP. However among the various hypotensive drug classes, 
CAI have demonstrated a consistent effect on ocular blood 
flow that is independent of IOP.37 Some data support the 
ability of CAI to enhance ocular blood flow regulation and 
suggest that the increase in blood flow exceeds that which 
is expected from their ocular hypotensive effect alone.42 The 
observed increase in ocular blood flow is likely caused by 
vasodilation of local ocular vessels, which has previously 
been reported to result from CAI-induced metabolic acidosis 
and subsequent elevation of carbon dioxide levels.43 This 
article will review CAI and their combined use with timolol 
in terms of their effects on the ocular circulation.
Carbonic anhydrase inhibitors  
and ocular blood flow
A variety of imaging technologies have been used to examine 
the effects of topical CAI on ocular blood flow. Each imaging 
technology has specific sites of measurement and inherent 
shortcomings. Therefore it is important to consider the limita-
tions of each imaging technology alongside the documented 
effects of CAI and their potential implications.
Pulsatile ocular blood flow
Several studies have documented increased pulsatile ocular 
blood flow (POBF) in subjects with OAG receiving a com-
bination of dorzolamide and timolol. It is important to note 
that POBF and ocular pulse amplitude (OPA) measurements 
are not methodologies which directly measure any aspect of 
ocular blood flow. They instead measure the fluctuation in 
IOP which may represent some aspect of total orbital pulse 
and perfusion, but this has not been established. Januleviciene 
et al compared the effects of dorzolamide/timolol fixed 
combination (DTFC) to those of latanoprost with respect 
to IOP and POBF in a randomized, open-label, cross-over 
study of 30 subjects with OAG.44 In this investigation there 
were no differences between the two study arms with respect 
to baseline IOP and POBF, and both treatments were found 
to similarly reduce IOP. However, DTFC increased pulse 
volume by 0.767 microliters (P = 0.0087) while latanoprost 
was not found to have a significant effect (P = 0.2407). These 
findings supported those from an earlier study by Manni et al 
in which the substitution of DTFC in place of timolol was 
found to similarly enhance POBF.45 The pulsatile component 
of ocular blood flow is believed to be measured by the ocular 
pulse amplitude (OPA) during POBF measurement. Schmidt 
et al investigated the effects of DTFC compared to that of 
timolol alone and found that DTFC significantly increased 
OPA while timolol alone had no effect.46 In patients with 
glaucoma, higher OPA has been shown to correlate with less 
severe glaucoma.47 Since POBF and OPA are based upon IOP 
measurements, it is unclear how POBF and OPA would differ 
significantly if measurements were done at different time 
points in a 24-hour day, especially in patients who exhibit 
night time/early morning dipping of systemic blood pressure 
or diurnal changes in IOP. Assessing diurnal fluctuations in 
IOP, blood pressure, and ocular blood flow are an area of 
needed research in glaucomatous patients.
These data suggest that augmentation of ocular blood 
flow may occur during of treatment with CAI. However, it 
should be noted that POBF and OPA are not direct measures 
of ocular blood flow, so study results should be interpreted 
with caution. Further, inter-individual variations have been 
shown to limit POBF analysis, although a coefficient of 
  reliability of 0.92 has been documented.48 Also, the relatively 
small sample sizes and use of single imaging technologies 
limits interpretation on the comprehensive impact of DTFC 
on ocular blood flow.
Color Doppler imaging
The most widely utilized imaging technology for investigat-
ing ocular blood flow in humans is color Doppler imaging 
(CDI).49 CDI has been utilized in dozens of studies which 
have investigated the effects of CAI on the retrobulbar 
circulation. Siesky et al compared the effects of DTFC and 
latanoprost plus timolol in a randomized, double-blind, 
cross-over study involving 16 patients.50 Both therapies 
produced statistically similar reductions of IOP (12.2% and 
13.9%, respectively; P = 0.5533) with similar heart rate and 
BP between treatments, suggesting minimal systemic vas-
cular alterations with topical use. In this study, only DTFC 
was associated with an increase in retrobulbar blood flow 
  velocities as measured by CDI. DTFC significantly increased 
end diastolic velocity (EDV) (P = 0.0168) and decreased the Clinical Ophthalmology 2010:4 236
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resistance to flow (P = 0.0279) in the central retinal artery 
(CRA). Peak systolic velocity (PSV) and EDV of the temporal 
posterior ciliary artery (PCA) were both increased by DTFC 
(P = 0.0125 and 0.0238, respectively). In vivo and in vitro 
studies have illustrated that parallel increases in PSV and 
EDV may be interpreted as an increase in volumetric blood 
flow.51,52 Of note, there were no significant differences in 
retinal hemodynamics as measured by Heidelberg retinal 
flowmetery (HRF), and there were no changes in visual func-
tion measured by visual acuity and contrast sensitivity.
Another study of the retrobulbar blood vessels by 
Uva et al compared DTFC to combined treatment with 
pilocarpine and timolol in 16 patients with OAG.53 The 
authors reported that although the latter treatment resulted 
in a greater decrease in IOP, only treatment with DTFC 
was associated with increased EDV and lower resistive 
index (RI) in the CRA (P  0.01). In another prospective, 
  randomized, cross-over study involving 22 subjects newly 
diagnosed with OAG, Martinez et al assessed the effects of 
DTFC and latanoprost on retrobulbar hemodynamics and 
IOP.54 IOP and CDI measurements, including PSV, EDV, 
and RI in the ophthalmic artery (OA) and short PCA, were 
similar at baseline. Both therapies were found to be equally 
  efficacious at reducing IOP, however, only treatment with 
DTFC significantly increased the EDV and decreased the RI 
in the OA and short PCA. A similar 32-subject, prospective, 
cross-over study comparing DTFC and a fixed combina-
tion of latanoprost and timolol (LTFC) found that while 
both treatments significantly lowered IOP only DTFC had 
beneficial vascular effects on retrobulbar vessels in patients 
with newly diagnosed OAG.55 In this study DTFC decreased 
the RI in the OA and short PCA while LTFC was found to 
increase RI in both vessels. A statistically significant increase 
in EDV in the OA and PCA was found with DTFC.
Other CAI, such as brinzolamide, have also been studied 
in combination with timolol for the treatment of primary 
OAG. In a 5-year prospective study, 146 participants were 
randomized to either dorzolamide 2% or brinzolamide 1%, 
each added to timolol 0.5%.56 The investigators found that 
dorzolamide, but not brinzolamide, augmented blood flow 
when added to timolol. Though both treatment arms similarly 
decreased IOP, only the combination of dorzolamide and 
timolol was associated with an increased EDV and decreased 
RI in the OA, short PCA, and CRA. A transient increase in 
retrobulbar flow was seen in the subjects receiving brinzol-
amide, which lasted for 6 months in the CRA and 12 months 
in the short PCA. These findings are in direct contrast to the 
many studies which suggest brinzolamide has similar blood 
flow influences to dorzolamide.37 The authors suggest that the 
  differing vasoactive effects of brinzolamide and dorzolamide 
may be explained by differing levels of inhibition of the 
carbonic anhydrase isoenzyme IV located in the endothelial 
cells of the choriocapillaris, as dorzolamide has 6.5 times 
the inhibitory activity of brinzolamide.43,57 It is more likely, 
however, that specific study limitations resulted in the dif-
ferences including inclusion of patients with elevated blood 
pressure and cardiovascular disease, insufficient study power 
to detect changes in the brinzolamide group (n = 35), and 
grouping of the short posterior ciliary arteries into a single 
parameter. More research is required to know for certain if 
differences exist between topical CAI treatments.
Though well-validated, CDI is not without limitations, 
the most significant being the inability to measure vessel 
diameter. Although CDI is very useful for measuring blood 
flow velocity and vascular resistance, this limitation prevents 
the measurement of volumetric blood flow and requires 
that assumptions be made when interpreting hemodynamic 
parameters. A significant degree of operator dependence 
is inherent to CDI, and due to study design, several of the 
previously mentioned studies did not document an index of 
reproducibility. As with POBF, many of the studies utilize 
only CDI limiting interpretation on the comprehensive impact 
of DTFC on ocular blood flow. For detailed analysis of CDI 
reproducibility see articles by Harris et al.58–60
Scanning laser ophthalmoscopy
Scanning laser ophthalmoscopy is one of the only imaging 
technologies that provides direct visualization of the retinal 
microcirculation and has shown CAI-induced increases in 
retinal and choroidal circulations. Specifically, dorzolamide 
has been shown to accelerate retinal dye transit as measured 
by scanning laser ophthalmoscopy.61 In a 9-subject, open-
label, cross-over study, Harris et al compared dorzolamide 
to betaxolol with respect to IOP reduction, arteriovenous 
passage time (AVP), and blood flow velocity in the retro-
bulbar vessels. Both medications were found to have similar 
hypotensive actions. Neither drug was found to alter the ret-
robulbar hemodynamics as measured by CDI. Dorzolamide, 
but not betaxolol, was found to accelerate inferotemporal 
arteriovenous passage of fluorescein dye. This acceleration 
of dye transit could be due to direct attenuation of vascular 
resistance or to venodilation. The authors speculate that 
regional variations in retinal responsiveness may explain 
why the increase was limited to the inferotemporal retina as 
regionally differing levels of responsiveness to vasodilator 
and vasoconstrictor stimuli have been documented.62Clinical Ophthalmology 2010:4 237
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In another study, Harris et al found that when compared 
with timolol, DTFC results in a greater decrease in AVP 
time (2.13 to 1.76 seconds, P = 0.01) in the superior retinal 
vasculature.63 Combined treatment also resulted in a greater 
IOP reduction (14.7 to 13.4 mmHg, P  0.05), making it 
difficult to determine if the reported hemodynamic changes 
are IOP-independent.
These findings must be carefully interpreted as short-
ened transit time is not a direct index of retinal blood 
flow.64 Nonetheless, acceleration of AVP has been shown 
to be consistent with increased blood flow suggesting CAI 
increases retinal blood flow.65 As with other investigations 
using different devices, relatively small sample sizes also 
limit interpretation. Further, the relatively invasive nature 
of scanning laser ophthalmoscopy and subsequent dye injec-
tions has limited its continued use in blood flow research in 
recent years.
Summary
Many imaging modalities are used to measure different hemo-
dynamic parameters, each with its own advantages and limita-
tions. Certain assumptions must be made with each technology, 
and therefore the interpretation of individual hemodynamic 
parameters must be assessed with caution. Relatively small 
sample sizes and many investigations utilizing only a single 
blood flow methodology further inhibit definitive analysis. 
Nevertheless, there is a growing body of evidence demon-
strating that CAI possess the ability to augment ocular blood 
flow. The most comprehensive analysis on the subject, a recent 
meta-analysis of 13 studies conducted between 1966 and 2006, 
revealed that treatment with topical CAI was associated with 
increased ocular blood flow velocities in the CRA, primary 
retinal artery branches, and short PCA.37
The mechanism by which CAI may elevate retinal, 
  chorodial, and retrobulbar blood flow remains unclear. 
Increased ocular perfusion pressure via IOP reduction is 
one likely mechanism. However, in several studies, CAI 
have been found to increase ocular blood flow compared to 
other treatments with similar IOP reduction. Therefore, an 
IOP-independent mechanism of increasing ocular circula-
tion during CAI may be present. It is plausible that carbonic 
anhydrase inhibition may directly relax local resistance in 
vessels as systemic CAI have been known to increase both 
cerebral66 and retinal67 blood flow by pressure independent 
mechanisms. Blockade of carbonic anhydrase in local tissues 
may therefore increase tissue CO2 concentrations and/or lower 
tissue pH resulting in vascular dilation and increased blood 
flow.67–70 With the limitations of current technology and the 
limited body of work that exists, current theories of the direct 
effects of CAI on ocular blood flow require further study.
While both dorzolamide and brinzolamide CAI have been 
available for some time, the fixed combination brinzolamide 
1% and timolol 0.5% (Azarga®) has recently been introduced 
for treatment of OAG. Azarga has been shown in a random-
ized controlled trial of 523 patients to significantly lower 
IOP more than either monotherapy.71 The effects of Azarga 
on ocular blood flow and ocular perfusion pressure are cur-
rently unknown.
Implications of CAI treatment  
on long term visual function  
and structure
In recent decades, many studies have revealed associations 
between compromised ocular blood flow, vascular dysregula-
tion, and glaucoma. However, currently there is insufficient 
evidence linking the reductions in ocular blood flow to the 
onset or progression of glaucoma.72 Pilot research describing 
the relationships between OAG and decreased ocular blood 
flow have formed a basis for establishing the role of vascular 
dysregulation in the pathogenesis of glaucoma. However, only 
multi-center, long-term prospective investigations combin-
ing visual field (VF) and optic nerve head (ONH) structure 
are capable of elucidating the role of ocular blood flow as 
a definite risk factor for the incidence and progression of 
glaucomatous optic neuropathy.
The relationship between ocular blood 
flow and visual function
Ocular blood flow and visual function
Several studies have addressed the relationship between ocular 
blood flow and visual function. Plange et al found that asym-
metry in the visual field (VF) corresponds to asymmetrical 
retrobulbar blood flow velocity of glaucoma patients measured 
by CDI.73 Zeitz et al also reported a correlation between VF 
progression and blood flow velocity in the short PCA which 
nourish the ONH.74 Galassi et al reported that patients with 
stable VF had higher EDV and lower vascular resistance in 
the OA.75 Patients with a vascular resistance greater than 
0.78 in the OA had 6-times the risk of VF deterioration. 
Martinez et al supported this finding, suggesting a correlation 
between RI greater than 0.72 in the OA and increased VF pro-
gression over a period of 3 years.76 Satilmis et al also reported 
that lower baseline flow velocities and higher vascular resis-
tance in the CRA were measured in patients with faster VF 
progression, unrelated to the extent of existing damage.77Clinical Ophthalmology 2010:4 238
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Examining the retinal microcirculation, Lam et al evaluated 
asymmetric VF damage and retinal capillary blood flow using 
HRF and reported a significant decrease in blood flow in eyes 
with worse VF damage as compared to the fellow eye.78 Sato 
et al also reported that a reduction in capillary blood flow at 
the neuroretinal rim in normal tension glaucoma patients was 
associated with corresponding deterioration in VF.79
Local and systemic factors other than glaucoma have also 
shown to affect ocular blood flow and VF outcomes. Sato et al 
showed that a reduction in neuroretinal rim blood flow due to 
scleral buckle surgery caused a progressive VF defect which 
stabilized after the buckle was removed.80 Improvements in 
ocular blood flow and mean deviation of the VF have also 
been observed after carotid endarterectomy.81
In a similar capacity to studies involving CAI therapies, 
relatively small sample sizes and many investigations utiliz-
ing only a single blood flow methodology limit the conclu-
sions from these pilot studies. Only larger, comprehensive 
investigations of ocular blood flow and visual function 
(preferably multi-center) can definitively conclude a causal 
relationship between reduced ocular blood flow and glaucoma 
progression.
Ocular blood flow and visual function  
in relation to CAI
A small number of studies have addressed the relation-
ship between CAI, ocular blood flow, and visual function. 
Martinez performed a 4-year prospective study evaluating 
the long-term effect of adding dorzolamide 2% twice daily 
to timolol maleate 0.5% twice daily on IOP, retrobulbar blood 
flow, and VF progression in a cohort of 40 patients.82 The 
authors concluded that the addition of dorzolamide 2% to 
timolol 0.5% was associated with a significant reduction in 
IOP, increase in retrobulbar blood flow in the OA and short 
PCA, and a reduction in the risk of VF progression by 58% 
as compared to treatment with timolol alone. However, this 
study has several important limitations. Most notably, the eye 
with the worse VF damage was treated with dorzolamide while 
the fellow eye with less damage served as the control. Due to 
regression to the mean effect, the eye with less severe disease 
is more likely to experience glaucoma progression than the 
dorzolamide treated eye. There was a 13.1% difference in 
mean IOP between the dorzolamide study eye and control eye 
which in itself can predict reduced progression regardless of 
a presumed additional effect on blood flow by dorzolamide. 
The small sample size (n = 40) also limits the conclusions 
as a whole. The results of the study also differ substantially 
from the results of the European Glaucoma Prevention 
Study (EGPS),83 a much larger, randomized, double-blind, 
controlled study. In the EGPS, 1081 patients with ocular 
hypertension (OHT) were enrolled by 18 European centers 
and were randomized to treatment with dorzolamide 2% or 
placebo. The efficacy end points were VF or change in ONH 
structure. Although dorzolamide reduced IOP by 15%–22% 
throughout the 5 years of the study, the EGPS failed to detect 
a statistically significant difference between medical therapy 
and placebo in reducing the incidence of OAG.
Another study evaluated visual function after application 
of dorzolamide, timolol or latanoprost in 14 newly diagnosed 
OAG patients.84 Ocular hemodynamics were assessed 
using fluorescein angiography by means of a scanning laser 
  ophthalmoscope. Visual function using VF evaluation was 
also evaluated. Treatment with dorzolamide shortened AVP. 
Given that prolonged AVP times have been proven to be 
associated with glaucoma progression,85 it was concluded 
by the study that dorzolamide may provide VF and optic 
nerve head preservation by increasing retinal blood flow to 
the peripapillary ocular tissue. One significant limitation of 
this study was a small sample size.
A recent study published by Martinez investigated the 
effects of treatment with either dorzolamide 2% (DT) or 
brinzolamide 1% (BT), each added to timolol 0.5%, over a 
5-year period, with respect to VF progression.86 The study 
showed that VF progression correlated with lower EDV 
in the OA and short PCA. Treatment with DT lowered the 
risk for progression more significantly than BT. These find-
ings should be cautiously interpreted since both treatments 
are very similar. In addition to possibly being statistically 
underpowered (n = 35 for BT group), uneven inclusion of 
bilateral glaucoma, systemic hypertension, and cardiovascu-
lar disease as well as VFs with false positives of up to 20% 
limit these results.
These studies support the role of increasing ocular blood 
flow to preserve visual function but fail to provide adequate 
evidence individually. However, only larger, adequately pow-
ered, multi-center trials monitoring VF and ocular blood flow 
outcomes associated with various glaucoma treatments are 
capable of providing confirmation of these studies.
The relationship between ocular  
blood flow and structure
Currently, there is a lack of information on CAI treatment, 
blood flow, and the structure of the ONH. There have been 
only a few studies which have investigated the relationship 
between ocular blood flow and ONH structure. Logan et al 
reported lower retinal blood flow in glaucoma patients as Clinical Ophthalmology 2010:4 239
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compared to controls.87 They found a significant relationship 
between retinal blood flow and structural damage to the ONH. 
Hafez et al showed that OAG patients had significantly lower 
blood flow in the ONH compared to OHT patients and nor-
mal controls.88 There was an inverse correlation between the 
blood flow at the neuroretinal rim and the cup to disc (C/D) 
ratio. In a study using CDI and scanning laser polarimetry, 
it was reported that OAG patients had statistically significant 
thinning of the retinal nerve fiber layer, reduced blood flow, 
and increased vascular resistance to flow as compared to 
age-matched healthy subjects.89
In a recent publication, Januleviciene et al compared 
LTFC to DTFC in a prospective, randomized, double-masked 
study.90 There were similar statistically significant IOP reduc-
tions in both treatment groups. There was no difference in VF 
progression or retinal nerve fiber layer thickness, as measured 
by scanning laser polarimetry, between the two groups after 
one year of treatment. However, there was a statistically 
  significant decrease in the RI of the OA and short PCA in the 
DTFC group compared to the LTFC group. There was also a 
statistically significant individual change from baseline PSV 
and EDV of the OA and CRA in the DTFC group.
As with the pilot data from visual function investigations, 
these studies are limited by relatively small sample sizes and 
limitations of patient populations and imaging technologies. 
Only larger, adequately powered multi-center trials moni-
toring structure and ocular blood flow outcomes associated 
with various glaucoma treatments are capable of providing 
confirmation of these pilot studies.
Conclusions
Although the World Glaucoma Association Consensus rec-
ognized that CAI have been shown to improve ocular blood 
flow beyond their hypotensive and perfusion pressure effects, 
the relationship between ocular blood flow, visual func-
tion, and ONH structure in patients with OAG has not been 
definitively established. Currently, only pilot data from small 
studies are available on CAI, ocular blood flow, and visual 
function and structure. Conclusive findings from current 
studies investigating the relationship between ocular blood 
flow, VF, and optic nerve head structure are limited by their 
use of differing imaging techniques, small sample sizes and 
methodological limitations. Current data are only suggestive 
of a link between ocular blood flow and glaucomatous VF 
loss, and only large-scale, multi-center, longitudinal studies 
utilizing uniform measurements of blood flow, retinal, and 
optic nerve structure and visual function are capable of 
  providing sufficient evidence of such a relationship.
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